Lonza strengthens its bioconjugation capacities at Visp, in the canton of Valais, with two new manufacturing suites.
- The expansion of bioconjugation capabilities will provide additional manufacturing capacity for launch and commercial supply, responding to growing market demand
- 2,000 m2 of production space will include two additional production suites and supporting infrastructure
- A significant increase in bioconjugation capacity will enable Lonza to offer its expertise to a broad customer base and meet the expected increase in approvals
The expansion will add two 1,200-liter multi-purpose manufacturing rooms and manufacturing-related infrastructure to the existing bioconjugation facility in Visp for launch and commercial supply.
“We continue to see strong growth in the bioconjugate field, as DCs and other bioconjugate drugs make increasing progress towards commercialization. This investment in our versatile commercial bioconjugation capability meets growing market demand, enables us to support our customers’ growth, and offers a flexible, integrated service for bioconjugate manufacturing.” commented Christian Morello, Vice President, Head of Bioconjugates, Lonza.
